The team has discovered that for acute myeloid leukemia (AML) patients, there is a dopamine receptor pathway that becomes abnormally activated in the cancer stem cells. This inspired the clinical investigation of a dopamine receptor-inhibiting drug thioridazine as a new therapy for patients, and their focus on adult AML has revealed encouraging results.
from Latest Science News -- ScienceDaily https://ift.tt/3diJoRt
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment